{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209005","form_type":"8-K","ticker":"PHAT","cik":"0001783183","company_name":"Phathom Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.215995+00:00","generated_at":"2026-06-11T18:38:47.048407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phathom Q2 net loss $41.0M; PDUFA dates Oct/Nov 2023 for VOQUEZNA","bullets":["Net loss $41.0M in Q2 2023, improved from $50.9M in Q2 2022.","Cash $248.8M at June 30; $100M available from Hercules on Oct 1, $175M upon Erosive GERD approval.","FDA PDUFA dates: Oct 30 for VOQUEZNA H. pylori packs; Nov 17 for Erosive GERD NDA.","Completed public offering May 2023 with $141.4M net proceeds.","Phase 3 PHALCON-NERD-301 completed; regulatory submission for Non-Erosive GERD on track H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209005","json":"https://secwatch.observer/filing/0001193125-23-209005.json","markdown":"https://secwatch.observer/filing/0001193125-23-209005.md","text":"https://secwatch.observer/filing/0001193125-23-209005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/0001193125-23-209005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/d491223d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:38:47.048407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e398d534af59aae17adaafb2b48a6c086c406cb3","claim":"Phathom Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income $41.0 million.","evidence_excerpt":"Net loss for the second quarter ended June 30, 2023, was $41.0 million, compared to $50.9 million for second quarter 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/0001193125-23-209005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$41.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}